MedTrace Logo

Behavioral Effects of Drugs Inpatient 44 Neurobehavioral Mechanisms of Opioid Choice

NCT06312657 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2026-03-30

Study results available
· View outcomes & findings →

Summary

The objective of this protocol is to use probabilistic choice tasks to determine the impact of withdrawal and drug cues on decision-making in individuals with opioid use disorder and physical opioid dependence.

Conditions

Interventions

BEHAVIORAL

Drug Cue

Individualized drug cues paired with choice options reinforced by $0.25

BEHAVIORAL

Money

Two money values will be tested ($0.25 and $4.00)

DRUG

Withdrawal

Participants will be maintained on an opioid agonist. Placebo will be substituted to produce mild-to-moderate withdrawal.

DRUG

Remifentanil

IV remifentanil will be made available as one of the choice options in some sessions.

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Joshua A. Lile, Ph.D.

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2025-03-28
Completion
2025-03-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06312657 on ClinicalTrials.gov